Literature DB >> 15986128

Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.

U Kumar1, S I Grigorakis, H L Watt, R Sasi, L Snell, P Watson, S Chaudhari.   

Abstract

Somatostatin receptors (SSTRs) have been identified in most hormone-producing tumors as well as in breast cancer. In the present study, we determined SSTR1-5 expression in primary ductal NOS breast tumors through semi-quantitative RT-PCR and immunocytochemistry. The results from the analysis of 98 samples were correlated with several key histological markers and receptor expression. All five SSTR subtypes are variably expressed at the mRNA level in breast tumors with 91% of samples showing SSTR1, 98% SSTR2, 96% SSTR3, 76% SSTR4, and 54% SSTR5. SSTR1-5 are localized to both tumor cells and the surrounding peritumoral regions as detected by immunocytochemistry. Levels of SSTR mRNA, when corrected for beta-actin levels, were highest for SSTR3 followed by SSTR1, SSTR2, SSTR5, and SSTR4. Furthermore, there was good correlation between mRNA and protein expression with 84% for SSTR1, 79% for SSTR2, 89% for SSTR3, 68% for SSTR4, 68% for SSTR5, and 78% for all five receptors. SSTR1, 2 and 4 were correlated with ER levels whereas SSTR2 showed an additional correlation with PR levels. These correlations were independent of patient age and histological grade. Moreover, using immunocytochemistry, blood vessels exhibited receptor-specific localization for SSTR2 and SSTR5. Our results indicate significant correlations between mRNA and protein expression along with receptor-specific correlations with histological markers as well as ER and PR levels. Differential distribution of SSTR subtypes in tumors and receptor-specific expression in vascular structures may be considered as a novel diagnosis for breast tumors with receptor subtype agonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986128     DOI: 10.1007/s10549-005-2414-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  33 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model.

Authors:  Eric F Lock; Nour Abdo; Ruili Huang; Menghang Xia; Oksana Kosyk; Shannon H O'Shea; Yi-Hui Zhou; Alexander Sedykh; Alexander Tropsha; Christopher P Austin; Raymond R Tice; Fred A Wright; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2012-01-19       Impact factor: 4.849

3.  Italian Society of Endocrinology Career Award Lecture: from somatostatin to…somatomedin.

Authors:  D Ferone
Journal:  J Endocrinol Invest       Date:  2012-08-29       Impact factor: 4.256

Review 4.  Cross-talk and modulation of signaling between somatostatin and growth factor receptors.

Authors:  Ujendra Kumar
Journal:  Endocrine       Date:  2011-08-26       Impact factor: 3.633

5.  Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.

Authors:  H L Watt; Z Rachid; B J Jean-Claude
Journal:  J Neurooncol       Date:  2010-05-14       Impact factor: 4.130

6.  Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma.

Authors:  Patrick G Buckley; Leah Alcock; Kenneth Bryan; Isabella Bray; Johannes H Schulte; Alexander Schramm; Angelika Eggert; Pieter Mestdagh; Katleen De Preter; Jo Vandesompele; Frank Speleman; Raymond L Stallings
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

7.  Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry.

Authors:  L E A Wildemberg; L Vieira Neto; D F Costa; L E Nasciutti; C M Takiya; L M Alves; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2011-09-06       Impact factor: 4.256

8.  Evaluation of Pan-SSTRs Targeted Radioligand [64Cu]NOTA-PA1 Using Micro-PET Imaging in Xenografted Mice.

Authors:  Fei Liu; Xiaoyi Guo; Teli Liu; Xiaoxia Xu; Nan Li; Chiyi Xiong; Chun Li; Hua Zhu; Zhi Yang
Journal:  ACS Med Chem Lett       Date:  2020-02-12       Impact factor: 4.345

9.  The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells.

Authors:  Yong He; Xiao-Mei Yuan; Ping Lei; Sha Wu; Wei Xing; Xiao-Li Lan; Hui-Fen Zhu; Tao Huang; Guo-Bing Wang; Rui An; Yong-Xue Zhang; Guan-Xin Shen
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

10.  Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.

Authors:  Sneha Singh; Rishi K Somvanshi; Vandana Panda; Ujendra Kumar
Journal:  Endocrine       Date:  2020-04-25       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.